M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid, and Oral Solid Dose Capacity —— Enhancements Strengthen ...
LGM Pharma is making strategic investments to support the growing need for high-quality domestic drug manufacturing,” “We have several prescription products in development, including both 505 (b) (2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results